Judith I Tsui1, Claire M Miller2, John D Scott3, Maria A Corcorran3, Julia C Dombrowski3, Sara N Glick3. 1. Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA. Electronic address: tsuij@uw.edu. 2. Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA. 3. Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.
Abstract
BACKGROUND: To describe the "continuum of care" for hepatitis C virus (HCV) and related health service utilization among persons who inject drugs (PWID) in the Seattle metropolitan area. METHODS: The study analyzed data from the 2015 National HIV Behavioral Surveillance system focused on PWID, which included local questions on HCV treatment and testing. We calculated respondent driven sampling (RDS)-adjusted percentages of participants who had completed each step of the care continuum and compared healthcare harm reduction services among participants who were HCV + vs. HCV- using bivariate analyses. RESULTS: 513 PWID were screened for HCV antibodies (Ab). Of those, 59.7% were HCV Ab+. Among those HCV Ab+, 86.4% had been tested for HCV at least once; 69.9% reported a previous diagnosis. Of those diagnosed, 55.9% had received a confirmatory test, 17.2% had ever received any medications for HCV, and 7.2% had completed treatment. The majority of HCV Ab + participants had seen a health care provider in the past 12 months (85.6%). CONCLUSIONS: There is a large gap between HCV screening and treatment among Seattle area PWID.
BACKGROUND: To describe the "continuum of care" for hepatitis C virus (HCV) and related health service utilization among persons who inject drugs (PWID) in the Seattle metropolitan area. METHODS: The study analyzed data from the 2015 National HIV Behavioral Surveillance system focused on PWID, which included local questions on HCV treatment and testing. We calculated respondent driven sampling (RDS)-adjusted percentages of participants who had completed each step of the care continuum and compared healthcare harm reduction services among participants who were HCV + vs. HCV- using bivariate analyses. RESULTS: 513 PWID were screened for HCV antibodies (Ab). Of those, 59.7% were HCV Ab+. Among those HCV Ab+, 86.4% had been tested for HCV at least once; 69.9% reported a previous diagnosis. Of those diagnosed, 55.9% had received a confirmatory test, 17.2% had ever received any medications for HCV, and 7.2% had completed treatment. The majority of HCV Ab + participants had seen a health care provider in the past 12 months (85.6%). CONCLUSIONS: There is a large gap between HCV screening and treatment among Seattle area PWID.
Authors: Douglas A E White; Erik S Anderson; Sarah K Pfeil; Tarak K Trivedi; Harrison J Alter Journal: Ann Emerg Med Date: 2015-08-04 Impact factor: 5.721
Authors: Brianna L Norton; Julia Fleming; Marcus A Bachhuber; Meredith Steinman; Joseph DeLuca; Chinazo O Cunningham; Nirah Johnson; Fabienne Laraque; Alain H Litwin Journal: Int J Drug Policy Date: 2017-08-12
Authors: Edward M Gardner; Margaret P McLees; John F Steiner; Carlos Del Rio; William J Burman Journal: Clin Infect Dis Date: 2011-03-15 Impact factor: 9.079
Authors: Soumitri Barua; Robert Greenwald; Jason Grebely; Gregory J Dore; Tracy Swan; Lynn E Taylor Journal: Ann Intern Med Date: 2015-08-04 Impact factor: 25.391
Authors: James W Galbraith; Ricardo A Franco; John P Donnelly; Joel B Rodgers; Jordan M Morgan; Andres F Viles; Edgar T Overton; Michael S Saag; Henry E Wang Journal: Hepatology Date: 2015-01-28 Impact factor: 17.425
Authors: Alain H Litwin; Kenneth A Harris; Shadi Nahvi; Philippe J Zamor; Irene J Soloway; Peter L Tenore; Daniel Kaswan; Marc N Gourevitch; Julia H Arnsten Journal: J Subst Abuse Treat Date: 2008-11-28
Authors: Alice K Asher; Carmen J Portillo; Bruce A Cooper; Carol Dawson-Rose; David Vlahov; Kimberly A Page Journal: Subst Use Misuse Date: 2016-05-24 Impact factor: 2.164
Authors: Jason Grebely; Jordan J Feld; David Wyles; Mark Sulkowski; Liyun Ni; Joe Llewellyn; Heshaam M Mir; Nika Sajed; Luisa M Stamm; Robert H Hyland; John McNally; Diana M Brainard; Ira Jacobson; Stefan Zeuzem; Marc Bourlière; Graham Foster; Nezam Afdhal; Gregory J Dore Journal: Open Forum Infect Dis Date: 2018-02-09 Impact factor: 3.835
Authors: Oluwaseun Falade-Nwulia; Risha Irvin; Alana Merkow; Mark Sulkowski; Alexander Niculescu; Yngvild Olsen; Kenneth Stoller; David L Thomas; Carl Latkin; Shruti H Mehta Journal: J Subst Abuse Treat Date: 2019-01-30
Authors: David Ortiz-Paredes; Afia Amoako; Taline Ekmekjian; Kim Engler; Bertrand Lebouché; Marina B Klein Journal: Front Public Health Date: 2022-06-24
Authors: Daniel Winetsky; Daniel Burack; Pantelis Antoniou; Bill Garcia; Peter Gordon; Matthew Scherer Journal: J Infect Dis Date: 2020-09-02 Impact factor: 5.226
Authors: Kathleen M Ward; Sean D McCormick; Mark Sulkowski; Carl Latkin; Geetanjali Chander; Oluwaseun Falade-Nwulia Journal: Int J Drug Policy Date: 2020-11-04
Authors: Maria A Corcorran; Judith I Tsui; John D Scott; Julia C Dombrowski; Sara N Glick Journal: Drug Alcohol Depend Date: 2021-01-11 Impact factor: 4.492
Authors: Oluwaseun Falade-Nwulia; Paul Sacamano; Sean D McCormick; Cui Yang; Greg Kirk; David Thomas; Mark Sulkowski; Carl Latkin; Shruti H Mehta Journal: Int J Drug Policy Date: 2020-03-02
Authors: Risha Irvin; Boatemaa Ntiri-Reid; Mary Kleinman; Tracy Agee; Jeffrey Hitt; Onyeka Anaedozie; Tolu Arowolo; Hope Cassidy-Stewart; CaSaundra Bush; Lucy E Wilson; Alexander J Millman; Noele P Nelson; Lauren Canary; Sherilyn Brinkley; Juhi Moon; Oluwaseun Falade-Nwulia; Mark S Sulkowski; David L Thomas; Michael T Melia Journal: J Viral Hepat Date: 2020-08-05 Impact factor: 3.517
Authors: Oluwaseun Falade-Nwulia; Kathleen M Ward; Sean McCormick; Shruti H Mehta; Stephanie R Pitts; Stephanie Katz; Geetanjali Chander; David L Thomas; Mark Sulkowski; Carl A Latkin Journal: J Viral Hepat Date: 2020-03-02 Impact factor: 3.517